According to Fortune Business Insights, the global intravenous immunoglobulins (IVIG) market size was valued at USD 14.85 billion in 2025 and is projected to grow from USD 16.04 billion in 2026 to USD 32.37 billion by 2034, exhibiting a CAGR of 8.28% during the forecast period. North America dominated the intravenous immunoglobulins market with a market share of 74.53% in 2025.
The market is witnessing robust growth due to the increasing prevalence of immunological and neurological disorders, rising awareness of immunoglobulin therapies, expanding plasma collection capacity, and growing approvals for new therapeutic indications. Advancements in plasma fractionation technologies and increasing healthcare investments are further supporting market expansion.
Key Market Drivers
Rising Prevalence of Immunodeficiency Disorders
The increasing incidence of primary immunodeficiency diseases and immune-related disorders is driving demand for intravenous immunoglobulin therapies.
Expanding Clinical Applications
Growing use of IVIG for neurological, autoimmune, hematological, and inflammatory diseases is broadening the market's therapeutic scope.
Increasing Plasma Collection and Fractionation Capacity
Investments in plasma collection centers and advancements in plasma processing technologies are improving immunoglobulin supply worldwide.
Market Restraints
Limited Plasma Availability
IVIG production depends on human plasma donations, making supply vulnerable to fluctuations in plasma collection.
High Treatment Costs
The complex manufacturing process and dependence on plasma-derived raw materials contribute to the high cost of IVIG therapies.
Get Sample PDF Here: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/intravenous-immunoglobulins-market-100593
Market Opportunities
Expansion of Approved Therapeutic Indications
Ongoing clinical research evaluating IVIG for additional autoimmune and neurological disorders is expected to create new market opportunities.
Growing Adoption of Home-Based Infusion Therapy
Increasing preference for homecare treatment is supporting demand for convenient IVIG administration and patient-centered healthcare services.